FDA updates capecitabine tablet labeling under Project Renewal
The agency approved revised labeling for capecitabine tablets, adding new indications and dosing regimens.
The FDA has approved updated labeling for capecitabine tablets, which includes new indications and new dosing regimens, according to the agency's own announcement title published on its drugs and cancer approvals page.
FDA approves updated drug labeling including new indications and dosing regimens for capecitabine tablets under Project Renewal1.
The source provided does not describe what Project Renewal is, its scope, or its purpose beyond this headline. It also does not specify the content of the new indications, the details of the new dosing regimens, the approval date, or any other supporting detail about the labeling change. Readers seeking the specifics of the revised indications or dosing instructions should consult the full prescribing information or the FDA's complete announcement, as the available document does not provide that level of detail.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.